FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2177453198> ?p ?o ?g. }

• W2177453198 abstract "Background Tumor necrosis factor–related apoptosis‐inducing ligand ( TRAIL ) has the ability to inhibit angiogenesis by inducing endothelial cell death, as well as being able to promote pro‐angiogenic activity in vitro. These seemingly opposite effects make its role in ischemic disease unclear. Using Trail −/− and wildtype mice, we sought to determine the role of TRAIL in angiogenesis and neovascularization following hindlimb ischemia. Methods and Results Reduced vascularization assessed by real‐time 3‐dimensional Vevo ultrasound imaging and CD 31 staining was evident in Trail −/− mice after ischemia, and associated with reduced capillary formation and increased apoptosis. Notably, adenoviral TRAIL administration significantly improved limb perfusion, capillary density, and vascular smooth‐muscle cell content in both Trail −/− and wildtype mice. Fibroblast growth factor‐2, a potent angiogenic factor, increased TRAIL expression in human microvascular endothelial cell‐1, with fibroblast growth factor‐2‐mediated proliferation, migration, and tubule formation inhibited with TRAIL si RNA . Both fibroblast growth factor‐2 and TRAIL significantly increased NADPH oxidase 4 ( NOX 4) expression. TRAIL ‐inducible angiogenic activity in vitro was inhibited with si RNA s targeting NOX 4, and consistent with this, NOX 4 mRNA was reduced in 3‐day ischemic hindlimbs of Trail −/− mice. Furthermore, TRAIL ‐induced proliferation, migration, and tubule formation was blocked by scavenging H 2 O 2 , or by inhibiting nitric oxide synthase activity. Importantly, TRAIL ‐inducible endothelial nitric oxide synthase phosphorylation at Ser‐1177 and intracellular human microvascular endothelial cell‐1 cell nitric oxide levels were NOX 4 dependent. Conclusions This is the first report demonstrating that TRAIL can promote angiogenesis following hindlimb ischemia in vivo. The angiogenic effect of TRAIL on human microvascular endothelial cell‐1 cells is downstream of fibroblast growth factor‐2, involving NOX 4 and nitric oxide signaling. These data have significant therapeutic implications, such that TRAIL may improve the angiogenic response to ischemia and increase perfusion recovery in patients with cardiovascular disease and diabetes." @default.
• W2177453198 created "2016-06-24" @default.
• W2177453198 creator A5001887990 @default.
• W2177453198 creator A5022874472 @default.
• W2177453198 creator A5031619803 @default.
• W2177453198 creator A5044908880 @default.
• W2177453198 creator A5048884410 @default.
• W2177453198 creator A5057659269 @default.
• W2177453198 creator A5067172562 @default.
• W2177453198 creator A5069530949 @default.
• W2177453198 creator A5076681768 @default.
• W2177453198 creator A5086610545 @default.
• W2177453198 creator A5089883387 @default.
• W2177453198 date "2015-10-29" @default.
• W2177453198 modified "2023-10-17" @default.
• W2177453198 title "Tumor Necrosis Factor–Related Apoptosis‐Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia‐Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide–Dependent Mechanisms" @default.
• W2177453198 cites W1561178184 @default.
• W2177453198 cites W161287260 @default.
• W2177453198 cites W1910698471 @default.
• W2177453198 cites W1970718678 @default.
• W2177453198 cites W1977668440 @default.
• W2177453198 cites W1996004246 @default.
• W2177453198 cites W2009388311 @default.
• W2177453198 cites W2013430397 @default.
• W2177453198 cites W2014374142 @default.
• W2177453198 cites W2016556817 @default.
• W2177453198 cites W2017825538 @default.
• W2177453198 cites W2018407804 @default.
• W2177453198 cites W2019071548 @default.
• W2177453198 cites W2036793133 @default.
• W2177453198 cites W2037439427 @default.
• W2177453198 cites W2047246919 @default.
• W2177453198 cites W2051770764 @default.
• W2177453198 cites W2056217426 @default.
• W2177453198 cites W2058275368 @default.
• W2177453198 cites W2072440487 @default.
• W2177453198 cites W2074238578 @default.
• W2177453198 cites W2078727519 @default.
• W2177453198 cites W2081402974 @default.
• W2177453198 cites W2082690239 @default.
• W2177453198 cites W2086969742 @default.
• W2177453198 cites W2104614171 @default.
• W2177453198 cites W2116090753 @default.
• W2177453198 cites W2130190789 @default.
• W2177453198 cites W2130988210 @default.
• W2177453198 cites W2131131136 @default.
• W2177453198 cites W2132676842 @default.
• W2177453198 cites W2133093019 @default.
• W2177453198 cites W2144500845 @default.
• W2177453198 cites W2145998835 @default.
• W2177453198 cites W2146738245 @default.
• W2177453198 cites W2148306131 @default.
• W2177453198 cites W2150459982 @default.
• W2177453198 cites W2151323225 @default.
• W2177453198 cites W2153417050 @default.
• W2177453198 cites W2155873374 @default.
• W2177453198 cites W2159030877 @default.
• W2177453198 cites W2165921560 @default.
• W2177453198 cites W2166573361 @default.
• W2177453198 cites W2203228009 @default.
• W2177453198 doi "https://doi.org/10.1161/jaha.115.002527" @default.
• W2177453198 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4845240" @default.
• W2177453198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26572549" @default.
• W2177453198 hasPublicationYear "2015" @default.
• W2177453198 type Work @default.
• W2177453198 sameAs 2177453198 @default.
• W2177453198 citedByCount "41" @default.
• W2177453198 countsByYear W21774531982016 @default.
• W2177453198 countsByYear W21774531982017 @default.
• W2177453198 countsByYear W21774531982018 @default.
• W2177453198 countsByYear W21774531982019 @default.
• W2177453198 countsByYear W21774531982020 @default.
• W2177453198 countsByYear W21774531982021 @default.
• W2177453198 countsByYear W21774531982022 @default.
• W2177453198 countsByYear W21774531982023 @default.
• W2177453198 crossrefType "journal-article" @default.
• W2177453198 hasAuthorship W2177453198A5001887990 @default.
• W2177453198 hasAuthorship W2177453198A5022874472 @default.
• W2177453198 hasAuthorship W2177453198A5031619803 @default.
• W2177453198 hasAuthorship W2177453198A5044908880 @default.
• W2177453198 hasAuthorship W2177453198A5048884410 @default.
• W2177453198 hasAuthorship W2177453198A5057659269 @default.
• W2177453198 hasAuthorship W2177453198A5067172562 @default.
• W2177453198 hasAuthorship W2177453198A5069530949 @default.
• W2177453198 hasAuthorship W2177453198A5076681768 @default.
• W2177453198 hasAuthorship W2177453198A5086610545 @default.
• W2177453198 hasAuthorship W2177453198A5089883387 @default.
• W2177453198 hasBestOaLocation W21774531981 @default.
• W2177453198 hasConcept C123012128 @default.
• W2177453198 hasConcept C126322002 @default.
• W2177453198 hasConcept C134018914 @default.
• W2177453198 hasConcept C167734588 @default.
• W2177453198 hasConcept C170493617 @default.
• W2177453198 hasConcept C190283241 @default.
• W2177453198 hasConcept C202751555 @default.
• W2177453198 hasConcept C2776151105 @default.
• W2177453198 hasConcept C2777025900 @default.
• W2177453198 hasConcept C2777622882 @default.
• W2177453198 hasConcept C2778271429 @default.
• W2177453198 hasConcept C2779719074 @default.

• next